SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

Recent Analyst Ratings for $PCRX

$PCRX Press Releases

$PCRX Large Ownership Changes

Chat with this insight

Fastest customizable press release news feed in the world

Pacira BioSciences Reports First Quarter 2025 Financial Results

Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

This live feed shows all institutional transactions in real time.

2/14/23 1:31:32 PM ET

$PCRX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PCRX alert in real time by email

SC 13G/A 1 d443025dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

Pacira Biosciences Inc.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

695127100

(CUSIP Number)

December 30, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 11

CUSIP No. 695127100

Page 2 of 13

CUSIP No. 695127100

Page 3 of 13

CUSIP No. 695127100

Page 4 of 13

Item 1.

(a)

Name of Issuer

Pacira BioSciences Inc.

(b)

Address of Issuer’s Principal Executive Offices

5401 West Kennedy Boulevard, Suite 890, Tampa, FL 33609

Item 2.

(a)

Name of Person Filing

This Schedule 13G is jointly filed by Macquarie Group Limited, Macquarie Management Holdings Inc, Macquarie Investment Management Business Trust

(b)

Address of Principal Business Office or, if none, Residence

The principal business address of Macquarie Group Limited is 50 Martin Place Sydney, New South Wales, Australia. The principal business address of Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust is 2005 Market Street, Philadelphia, PA 19103.

(c)

Citizenship

Macquarie Group Limited—Sydney, New South Wales, Australia Corporation Macquarie Management Holdings Inc and Macquarie Investment Management Business Trust – incorporated or formed under the laws of the State of Delaware.

(d)

Title of Class of Securities

Common Stock

(e)

CUSIP Number

695127100

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


(a)	☐	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)	☐	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)	☒	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)	☒	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)	☐	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	☐	A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________

Page 5 of 13

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)

Amount beneficially owned:

See responses on the cover page hereto.

(b)

Percent of class:

See responses on the cover page hereto.

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote

See responses on the cover page hereto.

(ii)

Shared power to vote or to direct the vote

(iii)

Sole power to dispose or to direct the disposition of

See responses on the cover page hereto.

(iv)

Shared power to dispose or to direct the disposition of

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

See Exhibit A.

Item 8.

Identification and Classification of Members of the Group

Not applicable.

Item 9.

Notice of Dissolution of Group

Not applicable.

Page 6 of 13

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 7 of 13

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Macquarie Group Limited		February 14, 2023
		Date

/s/ Michael Wainer		/s/ Charles Glorioso
Signature		Signature

Michael Wainer Associate Director		Charles Glorioso Division Director

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Macquarie Management Holdings, Inc.		February 14, 2023
		Date

/s/ Brian L. Murray
Signature

Brian L. Murray Chief Compliance Officer


Macquarie Investment Management Business Trust		February 14, 2023

		Date

/s/ Brian L. Murray
Signature

Brian L. Murray Chief Compliance Officer

Page 8 of 13

Get the next $PCRX alert in real time by email

Recent Analyst Ratings for

$PCRX

Date	Price Target	Rating	Analyst
1/30/2025	$8.00 → $25.00	Sell → Hold	Truist
8/13/2024	$30.00 → $8.00	Buy → Sell	Truist
8/12/2024	$42.00 → $11.00	Overweight → Neutral	Piper Sandler
8/12/2024	$45.00 → $10.00	Overweight → Underweight	JP Morgan
8/12/2024		Outperform → Mkt Perform	Raymond James
8/12/2024	$37.00 → $14.00	Outperform → Sector Perform	RBC Capital Mkts
7/3/2024	$38.00 → $25.00	Overweight → Equal Weight	Barclays
3/7/2024	$80.00 → $45.00	Overweight	JP Morgan

More analyst ratings

Names of Reporting Persons

Macquarie Group Limited

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☒ (b) ☐

SEC Use Only

Citizenship or Place of Organization

Sydney, New South Wales Australia